NCT01114555 2019-11-21Bevacizumab, Irinotecan and Temozolomide for Relapsed or Refractory NeuroblastomaMemorial Sloan Kettering Cancer CenterPhase 2 Completed34 enrolled 9 charts
NCT01492673 2019-10-29Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and NeuroblastomaMemorial Sloan Kettering Cancer CenterPhase 2 Completed9 enrolled 9 charts